ClearPoint Neuro (CLPT) Net Cash Flow Growth (3y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -87.88% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 129.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -65.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 33.47% |
| 10 | ClearPoint Neuro | 375.84 Mn | 340.24 Mn | 7.76 Mn | -21.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.55% |
| Dec 31, 2025 | -1.16% |
| Sep 30, 2025 | 11.64% |
| Jun 30, 2025 | 46.16% |
| Mar 31, 2025 | -20.13% |
| Dec 31, 2024 | 25.43% |
| Sep 30, 2024 | -42.77% |
| Jun 30, 2024 | 9.05% |
| Mar 31, 2024 | -35.14% |
| Dec 31, 2023 | -30.48% |
| Sep 30, 2023 | -15.79% |
| Jun 30, 2023 | 90.83% |
| Mar 31, 2023 | -36.01% |
| Dec 31, 2022 | 164.56% |
| Sep 30, 2022 | -57.72% |
| Jun 30, 2022 | -218.34% |
| Mar 31, 2022 | -94.02% |
| Dec 31, 2021 | -79.76% |
| Sep 30, 2021 | -9.05% |
| Jun 30, 2021 | -59.85% |
| Mar 31, 2021 | 200.74% |
| Mar 31, 2019 | 30.64% |
| Dec 31, 2018 | -26.79% |
| Sep 30, 2018 | -21.43% |
| Jun 30, 2018 | 34.60% |
| Mar 31, 2018 | 14.13% |
| Mar 31, 2016 | -30.86% |
| Dec 31, 2015 | 110.64% |
| Sep 30, 2015 | -38.39% |
| Jun 30, 2015 | -85.27% |
| Mar 31, 2015 | -56.41% |
| Dec 31, 2014 | 561.80% |
| Sep 30, 2014 | -60.54% |
| Jun 30, 2014 | 3.35% |
| Mar 31, 2014 | 51.20% |